Monographs on Vaccines and Immunosera - Revised Expert Guidance
Recommendation

29/30 April 2026
Perfect your skills in the ATMP world of GMP and Annex 1
At its 162nd session, the European Pharmacopoeia Commission (Ph. Eur.) approved a new edition of the Guide to the Preparation and Use of Monographs on Vaccines and Immunosera for Human Use. The document provides experts in the relevant pharmacopoeia groups with guidance on what information to include in the Ph. Monographs on vaccines and sera for human use. It also forms an important part of the harmonization of the style of the various monographs.
The new edition of the Guide takes into account the experiences of recent years in the preparation of monographs in this field and reflects the latest developments in Ph.
While the guide is aimed mainly at experts writing monographs on vaccines and sera, it also provides useful information to help users better understand the requirements and structure of these monographs. Thus it is aimed e.g. at
- Expert Group 15 (Vaccines and Immunosers for Human Use);
- Competent Authorities responsible for marketing authorisations for vaccines and immunosera;
- Official drug control laboratories (OMCLs);
- Manufacturers of vaccines and immune sera for human use;
- Bodies that procure vaccines and immune sera for healthcare; Public and private analytical laboratories working for one of the institutions above;
- The Ph. Eur. Secretariat and other departments of the European Directorate for the Quality of Medicine & Healthcare (EDQM).
The full document can be found at "Guide for the elaboration and use of monographs on vaccines and immunosera for human use".
Related GMP News
22.04.2026What are the GMP Requirements for ATMPs?
25.03.2026What are the GMP Requirements for Biotechnological Products?
18.03.2026Latest FDA Updates: Biosimilar Development Guidance
18.03.2026ECA ATMP Group publishes position paper on specifications considering patient-centricity
11.12.2025Utility of Comparative Efficacy Studies in Biosimilar Development
03.09.2025Standardisation of Monoclonal Antibodies (mAbs) by the EPC


